Do analysts recommend AKTX or SPRC?

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 271.65%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akari Therapeutics is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, AKTX or SPRC?

SciSparc has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A SciSparc $860K 3.53 -$12.18M N/A N/A

Is AKTX or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% SciSparc N/A N/A N/A

Do analysts rate CMMB or SPRC?

Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CMMB or SPRC?

Chemomab Therapeutics has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A SciSparc $860K 3.53 -$12.18M N/A N/A

Is CMMB or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% SciSparc N/A N/A N/A

Do analysts recommend SPRC or PHXM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, SPRC or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.53 -$12.18M N/A N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is SPRC or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A

Do analysts prefer MYNZ or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, MYNZ or SPRC?

SciSparc has higher revenue and earnings than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A SciSparc $860K 3.53 -$12.18M N/A N/A

Is MYNZ or SPRC more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A SciSparc N/A N/A N/A

Do analysts recommend BCDA or SPRC?

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,840.83%. Given BioCardia's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCardia is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BCDA or SPRC?

BioCardia has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 161.24 -$8.23M -$0.91 N/A SciSparc $860K 3.53 -$12.18M N/A N/A

Is BCDA or SPRC more profitable?

SciSparc's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% SciSparc N/A N/A N/A

SciSparc (SPRC) Competitors

$5.33 -0.39 (-6.82%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.38 +0.04 (+0.84%)

As of 07/24/2026 07:34 PM Eastern

Compare

SPRC vs. AKTX, CMMB, PHXM, MYNZ, and BCDA

Should you buy SciSparc stock or one of its competitors? MarketBeat compares SciSparc with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SciSparc include Akari Therapeutics (AKTX), Chemomab Therapeutics (CMMB), PHAXIAM Therapeutics (PHXM), Mainz Biomed (MYNZ), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry.

How does SciSparc compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

SciSparc has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
SciSparc	$860K	3.53	-$12.18M	N/A	N/A

Akari Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market.

In the previous week, Akari Therapeutics had 4 more articles in the media than SciSparc. MarketBeat recorded 6 mentions for Akari Therapeutics and 2 mentions for SciSparc. SciSparc's average media sentiment score of 0.96 beat Akari Therapeutics' score of 0.82 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Positive
SciSparc	Positive

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 271.65%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akari Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
SciSparc	N/A	N/A	N/A

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

SciSparc beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SciSparc's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
SciSparc	N/A	N/A	N/A

Chemomab Therapeutics has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
SciSparc	$860K	3.53	-$12.18M	N/A	N/A

In the previous week, SciSparc had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat SciSparc's score of 0.96 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
SciSparc	Positive

Chemomab Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Chemomab Therapeutics beats SciSparc on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to PHAXIAM Therapeutics?

SciSparc (NASDAQ:SPRC) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

SciSparc has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.53	-$12.18M	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

In the previous week, SciSparc had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for SciSparc and 0 mentions for PHAXIAM Therapeutics. SciSparc's average media sentiment score of 0.96 beat PHAXIAM Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the media.

Company	Overall Sentiment
SciSparc	Positive
PHAXIAM Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

25.1% of SciSparc shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

SciSparc beats PHAXIAM Therapeutics on 6 of the 8 factors compared between the two stocks.

How does SciSparc compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
SciSparc	N/A	N/A	N/A

SciSparc has higher revenue and earnings than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A
SciSparc	$860K	3.53	-$12.18M	N/A	N/A

In the previous week, SciSparc had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Mainz Biomed. SciSparc's average media sentiment score of 0.96 beat Mainz Biomed's score of 0.75 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Positive
SciSparc	Positive

25.1% of SciSparc shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

SciSparc beats Mainz Biomed on 6 of the 9 factors compared between the two stocks.

How does SciSparc compare to BioCardia?

BioCardia (NASDAQ:BCDA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

BioCardia has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market.

SciSparc's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
SciSparc	N/A	N/A	N/A

In the previous week, BioCardia and BioCardia both had 2 articles in the media. SciSparc's average media sentiment score of 0.96 beat BioCardia's score of 0.50 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Positive
SciSparc	Positive

BioCardia has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	161.24	-$8.23M	-$0.91	N/A
SciSparc	$860K	3.53	-$12.18M	N/A	N/A

20.6% of BioCardia shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,840.83%. Given BioCardia's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCardia is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioCardia and SciSparc tied by winning 6 of the 12 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.01M	$3.08B	$7.06B	$12.20B
Dividend Yield	N/A	2.07%	2.67%	9.41%
P/E Ratio	N/A	20.29	27.14	23.62
Price / Sales	3.53	339.68	523.81	89.60
Price / Cash	N/A	27.32	49.81	58.78
Price / Book	0.41	4.13	10.28	6.01
Net Income	-$12.18M	$65.94M	$3.60B	$331.99M
7 Day Performance	6.60%	-4.16%	-1.27%	-0.63%
1 Month Performance	-12.55%	-3.76%	-0.37%	-2.00%
1 Year Performance	-91.85%	9.94%	18.30%	13.62%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.9616 of 5 stars	$5.33 -6.8%	N/A	-92.3%	$3.01M	$860K	N/A	4	Short Interest Decrease Gap Up
AKTX Akari Therapeutics	3.3133 of 5 stars	$9.81 +5.5%	$32.33 +229.6%	-80.2%	$10.64M	N/A	N/A	9	News Coverage Positive News Analyst Downgrade
CMMB Chemomab Therapeutics	3.1473 of 5 stars	$1.43 -2.7%	$25.00 +1,648.3%	-68.8%	$10.59M	N/A	N/A	20
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MYNZ Mainz Biomed	0.4513 of 5 stars	$1.16 flat	N/A	-44.2%	$10.51M	$659.94K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. AKTX, CMMB, PHXM, MYNZ, and BCDA

How does SciSparc compare to Akari Therapeutics?

Summary

How does SciSparc compare to Chemomab Therapeutics?

Summary

How does SciSparc compare to PHAXIAM Therapeutics?

Summary

How does SciSparc compare to Mainz Biomed?

Summary

How does SciSparc compare to BioCardia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. AKTX, CMMB, PHXM, MYNZ, and BCDA

How does SciSparc compare to Akari Therapeutics?

Which has stronger earnings and valuation, AKTX or SPRC?

Which has more risk & volatility, AKTX or SPRC?

Does the media favor AKTX or SPRC?

Do analysts recommend AKTX or SPRC?

Is AKTX or SPRC more profitable?

Do institutionals and insiders have more ownership in AKTX or SPRC?

Summary

How does SciSparc compare to Chemomab Therapeutics?

Do insiders and institutionals have more ownership in CMMB or SPRC?

Is CMMB or SPRC more profitable?

Which has preferable valuation and earnings, CMMB or SPRC?

Does the media favor CMMB or SPRC?

Which has more risk and volatility, CMMB or SPRC?

Do analysts rate CMMB or SPRC?

Summary

How does SciSparc compare to PHAXIAM Therapeutics?

Which has more risk and volatility, SPRC or PHXM?

Is SPRC or PHXM more profitable?

Which has higher earnings and valuation, SPRC or PHXM?

Does the media refer more to SPRC or PHXM?

Do analysts recommend SPRC or PHXM?

Do institutionals & insiders have more ownership in SPRC or PHXM?

Summary

How does SciSparc compare to Mainz Biomed?

Do analysts prefer MYNZ or SPRC?

Which has more risk and volatility, MYNZ or SPRC?

Is MYNZ or SPRC more profitable?

Which has stronger valuation & earnings, MYNZ or SPRC?

Does the media favor MYNZ or SPRC?

Do insiders & institutionals have more ownership in MYNZ or SPRC?

Summary

How does SciSparc compare to BioCardia?

Which has more risk and volatility, BCDA or SPRC?

Is BCDA or SPRC more profitable?

Does the media prefer BCDA or SPRC?

Which has better earnings & valuation, BCDA or SPRC?

Do insiders and institutionals have more ownership in BCDA or SPRC?

Do analysts recommend BCDA or SPRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools